Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…

Published:2017 Issue:1 Volume:2 Page:e000162
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Thungappa Satheesh,Ferri Jose,Caglevic Christian,Passiglia Francesco,Raez Luis,Rolfo Christian^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung Cancer;Reck;N Engl J Med,2016

2. Press release: greater patient selection may be needed for first line nivolumab to improve. Progression-free survival in advanced lung Cancer;ESMO,2016

3. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung Cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

4. News: osimertinib combined with durvalumab in EGFR-mutant Non-Small-Cell lung Cancer. results from exploratory trial of evaluation of combination treatment;ELCC,2016

5. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in Non-Small cell lung Cancer: a retrospective analysis;Gainor;Clin Cancer Res,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VISTA: A Novel Checkpoint for Cancer Immunotherapy;Drug Discovery Today;2024-07

2. Prognostic value ofKRASmutations,TP53mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy;Journal of Clinical Pathology;2022-11-21

3. Potential of Black Phosphorus in Immune-Based Therapeutic Strategies;Bioinorganic Chemistry and Applications;2022-07-11

4. Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment;Thoracic Cancer;2022-07-03

5. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle;Therapeutic Advances in Medical Oncology;2022-01